Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Runimotamab in HER2-Expressing Cancers
jRCT2031200349Phase 1Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Aug 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label, single-arm trial of runimotamab in breast cancer, gastric cancer (GC), esophagogastric junction cancer and 1 more, sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Safety and dose-limiting toxicities and Adverse events. Started Aug 2021; status: active, not recruiting.
02
Drugs
runimotamab
03
Conditions
breast cancergastric cancer (GC)esophagogastric junction cancerHER2-overexpressing solid tumor
Beyond the preview
Go deeper on jRCT2031200349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200349.